Items of recent pandemic news: A resource for finding authorized therapeutics in the US; how long booster shots protect; an early study isolating ultrapotent antibodies from elite neutralizers; and a new variant on the Omicron variant. Plus a frippery. Quotes … Continue reading →
Items of recent pandemic news: Minnesota’s oddly bright prospects; Israel offers a fourth shot; the end of the pandemic as a social phenomenon; and what happens when Omicron hits a population with pre-existing immunity. Plus a frippery. Quotes of the … Continue reading →
Items of recent pandemic news: CureVac’s second-generation vaccine does as well as Pfizer / BioNTech’s in a pre-clinical trial; the brain may participate directly in immune memory; and approval for boosters for all US adults. Plus a frippery. Boosters for … Continue reading →
This week the Update moves from its former strictly biweekly cadence to a weekly format; each issue will encompass a larger number of brief items. There may occasionally be longer features. Fear not, the frippery is here to stay. mRNA … Continue reading →
Two items of recent pandemic news: Studies point to long-lasting, possibly lifelong immunity from natural infection; and rapid developments in the highly political question of where SARS-CoV-2 came from. Plus news briefs and a pair of fripperies. Origin, again It … Continue reading →
Herewith three items of pandemic news you may have missed recently: The latest installment in the ongoing AstraZeneca saga; how the immunosuppressed respond to mRNA vaccination; and Minnesota’s opening up of eligibility for shots. Plus news briefs and a frippery. … Continue reading →
Herewith three items of pandemic news you may have missed recently: Evidence that post-infection people could need only one shot; asymptomatics and long Covid; and AstraZeneca on pause across Europe over safety concerns. Plus news briefs and a frippery. AstraZeneca … Continue reading →
Herewith three items of pandemic news you may have missed recently: One instance in Oregon of a scary variant; quantifying the variants’ immune escape; and the new CDC guidelines. Plus news briefs and a frippery. A year Before we dive … Continue reading →
Herewith three items of pandemic news you may have missed recently: Booking a shot in Minnesota; low dead-space syringes; and Norway is investigating the deaths of elderly vaccine recipients. Plus news briefs and a frippery. Norway urges caution before vaccinating … Continue reading →
Herewith three items of pandemic news you may have missed recently: How wearable computers could predict Covid-19; the complicated situation with autoantibodies; and the late-stage trial of German company CureVac’s vaccine candidate. Plus the accustomed frippery. CureVac’s candidate enters Phase … Continue reading →
Herewith three items of pandemic news you may have missed recently: cyber attacks against vaccine developers worldwide; a comprehensive clinical trials dashboard; and the elusive allure of SARS-CoV-2 sterilizing immunity. Plus the usual frippery. The promise of sterilizing immunity We … Continue reading →
Herewith three items of pandemic news you may have missed recently: a list of 50 voices you can trust; doubts that an EUA might be issued anytime soon; and more questions on how long immunity lasts. Plus the accustomed frippery. … Continue reading →
The Update has gone semi-weekly. Herewith three more items of pandemic news you may have missed recently: the next pandemic; the duration of immunity; and two new metrics that may portend severe Covid-19. Plus a frippery. Two New Metrics That … Continue reading →
Repeat infections with Covid-19 are back in the news: a Nevada man’s case was published in The Lancet, and an elderly, immune-compromised woman in the Netherlands died after a second infection. Still, there is little cause to worry. We touched … Continue reading →
We’re going to be stringing together Covid-19 and the immune system’s response to it with genes we inherited from Neanderthals. Bear with us. First, let’s look at a paper outlining a genetic defect that results in sub-par production of one … Continue reading →
